SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/19 – ‘R5’

On:  Monday, 3/30/20, at 3:36pm ET   ·   For:  12/31/19   ·   Accession #:  1640334-20-668   ·   File #:  1-12033

Previous ‘20-F’:  ‘20-F’ on 3/29/19 for 12/31/18   ·   Next:  ‘20-F’ on 3/29/21 for 12/31/20   ·   Latest:  ‘20-F’ on 5/2/23 for 12/31/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/20  Nymox Pharmaceutical Corp         20-F       12/31/19  107:5.1M                                   Pubco Reporting … Inc/FA

Annual Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report by a Foreign Non-Canadian Issuer      HTML    722K 
 4: EX-13.A     Annual or Quarterly Report to Security Holders      HTML     25K 
 5: EX-13.B     Annual or Quarterly Report to Security Holders      HTML     25K 
 2: EX-12.A     Statement re: Computation of Ratios                 HTML     30K 
 3: EX-12.B     Statement re: Computation of Ratios                 HTML     30K 
59: R1          Document and Entity Information                     HTML     54K 
92: R2          Consolidated Statements of Comprehensive Income     HTML     78K 
82: R3          Consolidated Statements of Financial Position       HTML     87K 
22: R4          Consolidated Statements of Financial Position       HTML     28K 
                (Parenthetical)                                                  
58: R5          Consolidated Statements of Cash Flow                HTML     93K 
91: R6          Consolidated Statements of Changes in Equity        HTML     73K 
81: R7          Business Activities and Basis of Presentation       HTML     37K 
21: R8          Going Concern Considerations                        HTML     30K 
60: R9          Significant Estimates                               HTML     28K 
97: R10         Significant Accounting Policies                     HTML     76K 
62: R11         New Accounting Standards and Interpretations        HTML     30K 
27: R12         Property and Equipment                              HTML     89K 
39: R13         Intangible Assets                                   HTML     29K 
96: R14         Accounts Payable and Accrued Liabilities            HTML     38K 
61: R15         Convertible Notes                                   HTML     40K 
26: R16         Operating Leases and Commitments                    HTML     42K 
38: R17         Share Capital                                       HTML     41K 
95: R18         Stock Options                                       HTML     51K 
63: R19         Share Based Compensation                            HTML     37K 
19: R20         Warrants                                            HTML     59K 
57: R21         Income Taxes                                        HTML     60K 
94: R22         Earnings Per Share                                  HTML     35K 
84: R23         Financial Instruments Fair Value Disclosures        HTML     29K 
18: R24         Finance Income and Finance Costs                    HTML     52K 
56: R25         Segment Disclosures                                 HTML     43K 
93: R26         Concentrations                                      HTML     32K 
83: R27         Related Party Transactions                          HTML     39K 
20: R28         Research and Development Expenses                   HTML     40K 
55: R29         Personnel Expenses                                  HTML     37K 
35: R30         Capital Disclosures and Financial Risk              HTML     29K 
24: R31         Foreign Exchange Risk                               HTML     28K 
64: R32         Credit Risk                                         HTML     30K 
98: R33         Interest Rate Risk                                  HTML     27K 
36: R34         Liquidity Risk                                      HTML     33K 
25: R35         Subsequent Events                                   HTML     28K 
65: R36         Significant Accounting Policies (Policies)          HTML    127K 
99: R37         Significant Accounting Policies (Tables)            HTML     29K 
37: R38         Property and Equipment (Tables)                     HTML     88K 
23: R39         Accounts Payable and Accrued Liabilities (Tables)   HTML     37K 
51: R40         Convertible Notes (Tables)                          HTML     35K 
16: R41         Commitments and Contingencies (Tables)              HTML     38K 
75: R42         Share Capital (Tables)                              HTML     36K 
85: R43         Stock Options (Tables)                              HTML     55K 
52: R44         Share Based Compensation (Tables)                   HTML     34K 
17: R45         Warrants (Tables)                                   HTML     55K 
76: R46         Income Taxes (Tables)                               HTML     65K 
86: R47         Earnings Per Share (Tables)                         HTML     33K 
53: R48         Finance Income and Finance Costs (Tables)           HTML     51K 
15: R49         Segment Disclosures (Tables)                        HTML     42K 
33: R50         Concentrations (Tables)                             HTML     31K 
47: R51         Related Party Transactions (Tables)                 HTML     35K 
101: R52         Research and Development Expenses (Tables)          HTML     39K  
68: R53         Personnel Expenses (Tables)                         HTML     36K 
32: R54         Liquidity risk (Tables)                             HTML     31K 
46: R55         Significant Accounting Policies (Details)           HTML     33K 
100: R56         Significant Accounting Policies (Details            HTML     28K  
                Narrative)                                                       
67: R57         New Accounting Standards and Interpretations        HTML     35K 
                (Details Narrative)                                              
34: R58         Property and Equipment (Details)                    HTML     60K 
45: R59         Property and Equipment (Details Narrative)          HTML     28K 
90: R60         Intangible Assets (Details Narrative)               HTML     38K 
79: R61         Accounts Payable and Accrued Liabilities (Details)  HTML     34K 
14: R62         Convertible Notes (Details)                         HTML     32K 
50: R63         Convertible Notes (Details Narrative)               HTML     40K 
88: R64         Operating Leases and Commitments (Details)          HTML     31K 
77: R65         Operating Leases and Commitments (Details 1)        HTML     34K 
12: R66         Operating Leases and Commitments (Details           HTML     40K 
                Narrative)                                                       
48: R67         Share Capital (Details)                             HTML     30K 
87: R68         Share Capital (Details Narrative)                   HTML     40K 
80: R69         Stock Options (Details)                             HTML     52K 
71: R70         Stock Options (Details 1)                           HTML     43K 
102: R71         Stock Options (Details Narrative)                   HTML     30K  
41: R72         Share Based Compensation (Details)                  HTML     34K 
28: R73         Share Based Compensation (Details Narrative)        HTML     38K 
74: R74         Warrants (Details)                                  HTML     48K 
105: R75         Warrants (Details Narrative)                        HTML     36K  
44: R76         Income Taxes (Details)                              HTML     43K 
31: R77         Income Taxes (Details 1)                            HTML     33K 
69: R78         Income Taxes (Details 2)                            HTML     84K 
106: R79         Income Taxes (Details Narrative)                    HTML     28K  
72: R80         Earnings Per Share (Details)                        HTML     31K 
103: R81         Financial Instruments Fair Value Disclosures        HTML     34K  
                (Details Narrative)                                              
42: R82         Finance Income and Finance Costs (Details)          HTML     47K 
29: R83         Segment Disclosures (Details)                       HTML     43K 
73: R84         Concentrations (Details)                            HTML     32K 
104: R85         Related Party Transactions (Details)                HTML     36K  
43: R86         Related Party Transactions (Details Narrative)      HTML     36K 
30: R87         Research and Development Expenses (Details)         HTML     41K 
70: R88         Personnel Expenses (Details)                        HTML     35K 
107: R89         Capital Disclosures and Financial Risk (Details     HTML     39K  
                Narrative)                                                       
89: R90         Foreign Exchange risk (Details Narrative)           HTML     28K 
78: R91         Credit risk (Details Narrative)                     HTML     34K 
13: R92         Interest rate risk (Details Narrative)              HTML     27K 
49: R93         Liquidity risk (Details)                            HTML     35K 
66: XML         IDEA XML File -- Filing Summary                      XML    195K 
40: EXCEL       IDEA Workbook of Financial Reports                  XLSX    101K 
 6: EX-101.INS  XBRL Instance -- nymx-20191231                       XML   1.64M 
 8: EX-101.CAL  XBRL Calculations -- nymx-20191231_cal               XML    146K 
 9: EX-101.DEF  XBRL Definitions -- nymx-20191231_def                XML    448K 
10: EX-101.LAB  XBRL Labels -- nymx-20191231_lab                     XML    907K 
11: EX-101.PRE  XBRL Presentations -- nymx-20191231_pre              XML    735K 
 7: EX-101.SCH  XBRL Schema -- nymx-20191231                         XSD    307K 
54: ZIP         XBRL Zipped Folder -- 0001640334-20-000668-xbrl      Zip    133K 


‘R5’   —   Consolidated Statements of Cash Flow


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.20.1
Consolidated Statements of Cash Flow - USD ($)
$ in Thousands
12 Months Ended
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $ (13,162) $ (10,594) $ (13,429)
Adjustments to reconcile net loss to net cash used in operating activities      
Depreciation 9 3 1
Stock-based compensation 3,011 3,814 6,297
Issued stock for service fee 1,330 101
Accretion expense and interest settled by share issuances 0 152
Amortization and others 556
Changes in operating assets and liabilities:      
Accounts receivable and other receivables (4) 73 (77)
Research tax credit receivable
Security deposit 12 (16)
Prepaid expense (18) (1)
Inventory 17 (25) (13)
Accounts payable and accrued liabilities 819 (1,156) 863
Net cash used in operating activities (7,430) (7,801) (6,206)
CASH FLOWS FROM INVESTING ACTIVITIES      
Purchase of property and equipment (36)
Net cash flows used in investing activities (36)  
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds from the issuance of share capital 5,000 14,932 5,039
Repayment of operating lease and financing obligation (277)    
Net cash provided from financing activities 4,723 14,932 5,039
Net (decrease) increase in cash and cash equivalents (2,707) 7,095 (1,167)
CASH AND CASH EQUIVALENTS      
Beginning of year 7,946 851 2,018
End of year 5,239 7,946 851
SUPPLEMENTAL DISCLOSURE      
Income taxes paid
Interest paid
NON-CASH INVESTING AND FINANCING ACTIVITIESACTIVITIES      
Shares and warrants issued on connection with convertible notes $ 1,171

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘20-F’ Filing    Date    Other Filings
Filed on:3/30/20
For Period end:12/31/19
12/31/1820-F
12/31/1720-F,  20-F/A
 List all Filings 
Top
Filing Submission 0001640334-20-000668   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 11:31:44.1am ET